Skip to main content

Meet the founder: Dr. Muhunthan Thillai, Qureight

7 July 2025

Backing the future of clinical trials with Qureight 

Powered by artificial intelligence, Qureight’s market leading technology allows pharmaceutical companies, hospitals and clinical research organisations to analyse medical images of the heart and lungs and more effectively measure the impact of new experimental drugs on lung function and disease progression. It has partnered with major players including AstraZeneca, Vicore Pharma and Cumberland Pharmaceuticals and holds data contracts across NHS England.

Since it was founded in 2018 and following investment from the VCT in early 2024, Dr. Muhunthan Thillai and the team have achieved remarkable milestones that demonstrate their vision and innovation.

Filmed in Cambridge, this interview offers a behind-the-scenes look at Qureight’s growth - from its early ambition to streamline drug development using AI and real-world data, to becoming a fast-growing company powered by world-class clinicians, software engineers and AI scientists.

Watch the video to learn:

  • How Qureight was founded by two full-time doctors
  • The company’s current achievements and partnerships
  • Its exciting pipeline of new products and deep-learning imaging models
  • What the future holds for this pioneering health-tech company.

We're proud to back Qureight on this journey. Its synthetic study arm, deep learning imaging models and real-time AI tools are already transforming how the biopharma industry approaches drug development.

Further reading

AIM at 30

Our portfolio companies

AIM: Looking forward with optimism

The VCT invests in small, high risk companies, which are mostly listed on AIM. These companies may have volatile share prices and the investments may be difficult to realise. VCT investors are also exposed to changes in legislation that may adversely affect the company’s status as a VCT and its ability to meet the investment objectives and/or reduce the level of achievable return. There can be no guarantee that the VCT will meet its objectives or that suitable investment opportunities will be identified. A failure to maintain the qualifying status could result in the VCT losing the tax reliefs previously obtained, resulting in adverse tax consequences for investors.

Important for shareholders

Our last cheque payment for dividends will be in July 2025. If you currently receive dividends by cheque, please provide your bank details before the next payment due in February 2026. You can update your details by contacting Equiniti on 0371 384 2030 or via the Shareview website.

Shareview online

Contact us

For all shareholder enquiries including valuations, dividend payments or transactions, please contact the admin team:

Call us +44 (0)1253 376 622
Email aimvct@canaccord.com

For further information about the VCT or its underlying investments, please contact the fund management team on +44 (0)207 523 4837 or send us a message.

Existing shareholder?

Please indicate below if you would like to receive the following communications by email. You can withdraw your consent at any time by clicking on the unsubscribe option in any email you receive or by emailing aimvct@canaccord.com.

Marketing communications and factsheets - I would like to receive offer updates, information about future fundraises, factsheets and other related marketing communications by email from Hargreave Hale AIM VCT (all marketing communications are approved by Canaccord Genuity Wealth Limited).

Marketing communication and factsheets tick box *

Shareholder updates - I would like to receive regular shareholder updates and information on shareholder events from Hargreave Hale AIM VCT.

Shareholder updates tick box *

By selecting one or both of the options above, you consent to the sending of updates by email.

Investment involves risk and you may not get back what you invest. It’s not suitable for everyone.

Investment involves risk and you may not get back what you invest. It’s not suitable for everyone.